Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Ceritinib: Additional Phase I data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Ceritinib (LDK378) Business: Cancer Molecular target: Anaplastic lymphoma kinase (ALK) Description: Oral small molecule anaplastic lymphoma kinase (ALK) …

    Published on 4/7/2014
  • Egalet-001 neurology data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Egalet-001 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Abuse-deterrent, extended-release, oral formulation of morphine Indication: …

    Published on 4/7/2014
  • Emapticap pegol: Phase IIa data

    Noxxon Pharma AG, Berlin, Germany Product: Emapticap pegol (NOX-E36) Business: Renal Molecular target: Monocyte chemoattractant protein-1 (MCP-1) (CCL2) Description: L-aptamer monocyte chemoattractant protein-1 (MCP-1; …

    Published on 4/7/2014
  • Evolocumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9…

    Published on 4/7/2014
  • Evolocumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9…

    Published on 4/7/2014
  • Evolocumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9…

    Published on 4/7/2014
  • Evolocumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9…

    Published on 4/7/2014
  • Evolocumab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Evolocumab (AMG 145) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9…

    Published on 4/7/2014
  • GSK1070916: Phase I data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK1070916, GSK1070916A Business: Cancer Molecular target: Aurora kinase B (AURKB) (Aurora-B); Aurora kinase C (AURKC) (Aurora-C) Description: Inhibitor of …

    Published on 4/7/2014
  • ISIS-APOCIIIRx: Final Phase II data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-APOCIIIRx (ISIS 304801) Business: Endocrine/Metabolic Molecular target: Apolipoprotein C-III (APOCIII) (APOC3) Description: Apolipoprotein C-III (…

    Published on 4/7/2014
  • LCZ696: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: LCZ696 Business: Cardiovascular Molecular target: Angiotensin II type 2 (AT2) receptor (ATGR2); Neutral endopeptidase (neprilysin) (MME) (NEP) (CD10) …

    Published on 4/7/2014
  • Melapuldencel-T: Phase I data

    California Stem Cell Inc., Irvine, Calif. Cellular Biomedicine Group Inc. (OTCQB:CBMG), Palo Alto, Calif. Product: Melapuldencel-T (TC-DC, Tumor Stem Cell Specific Dendritic Cell therapy, DC-TC) Business: Cancer …

    Published on 4/7/2014
  • Otezla apremilast: Additional Phase III data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Otezla apremilast (CC-10004) Business: Autoimmune Molecular target: Phosphodiesterase-4 (PDE-4); Interleukin-2 (IL-2) Description: Oral phosphodiesterase-4 (PDE-4) …

    Published on 4/7/2014
  • PBT2: Phase II data

    Prana Biotechnology Ltd. (ASX:PBT; NASDAQ:PRAN), Parkville, Australia Product: PBT2 Business: Neurology Molecular target: Beta amyloid Description: Metal protein-attenuating compound (MPAC) Indication: Treat Alzheimer's…

    Published on 4/7/2014
  • Pigmented Lesion Assay: Clinical trial data

    DermTech International Inc., La Jolla, Calif. Product: Pigmented Lesion Assay (formerly MelDTect test) Business: Diagnostic Molecular target: NA Description: Non-invasive melanoma detection assay using a 2-gene …

    Published on 4/7/2014
  • RecAP: Phase I data

    AM-Pharma B.V., Bunnik, the Netherlands Product: RecAP (recombinant Alkaline Phosphatase) Business: Renal Molecular target: Lipopolysaccharide (LPS) Description: IV recombinant human alkaline phosphatase Indication: …

    Published on 4/7/2014
  • Simeprevir: Additional Phase IIa data

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Simeprevir (Sovriad, Galexos, Olysio) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 4/7/2014
  • Sovaldi sofosbuvir: Additional Phase IIa data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Sovaldi sofosbuvir (GS-7977) (formerly PSI-7977) Business: Infectious Molecular target: HCV NS5B polymerase Description: Nucleotide analog HCV NS5B …

    Published on 4/7/2014
  • Sovaldi sofosbuvir: Phase III data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Sovaldi sofosbuvir (GS-7977) (formerly PSI-7977) Business: Infectious Molecular target: HCV NS5B polymerase Description: Nucleotide analog HCV NS5B …

    Published on 4/7/2014
  • Talimogene laherparepvec: Updated Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: Talimogene laherparepvec (formerly OncoVEX GM-CSF) Business: Cancer Molecular target: NA Description: Modified herpes simplex virus type 1 (HSV-1) encoding GM-CSF…

    Published on 4/7/2014
  • ACH-3102: Additional Phase II data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 3/17/2014
  • ACH-3102: Additional Phase IIa data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 3/17/2014
  • APPY1: Pivotal trial data

    Venaxis Inc. (NASDAQ:APPY), Castle Rock, Colo. Product: APPY1 (formerly AppyScore) Business: Diagnostic Molecular target: S100 calcium binding protein A8 (S100A8) (calgranulin A) (MRP8); S100 calcium binding protein A9…

    Published on 3/17/2014
  • Bosatria mepolizumab: Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Bosatria mepolizumab (SB-240563) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized IgG mAb against IL-5 Indication: …

    Published on 3/17/2014
  • Bosatria mepolizumab: Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Bosatria mepolizumab (SB-240563) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized IgG mAb against IL-5 Indication: …

    Published on 3/17/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993